Evidence map›Paper›PMID 42909898›Full record

ArticleBrain communications2026

Regional blood-brain barrier dysfunction maps to lower performance in cognitive ageing.

Sheida Mirloo, Sheizaf Shpilberg, Noam Druker, Rotem Saar-Ashkenazy, Ofer Prager, Shai Baruch Neustaedter, Gal Ben-Arie, Ilan Shelef, Lyna Kamintsky, Yonatan Serlin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sheida MirlooDepartment of Medical Neuroscience and the Brain Repair Center, Dalhousie University, Faculty of Medicine, Halifax, NS B3H 4R2, Canada.
Sheizaf ShpilbergDepartments of Physiology and Cell Biology, The Zelman Center for Brain Science Research, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
Noam DrukerDepartments of Physiology and Cell Biology, The Zelman Center for Brain Science Research, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
Rotem Saar-AshkenazyFaculty of Social Work, Ashkelon Academic College, Ashkelon 78211, Israel.
Ofer PragerDepartments of Physiology and Cell Biology, The Zelman Center for Brain Science Research, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
Shai Baruch NeustaedterDepartment of Psychiatry, Soroka University Medical Center, Beer-Sheva 8410101, Israel.
Gal Ben-ArieDepartment of Diagnostic Imaging, Soroka University Medical Center, Beer Sheva 8410101, Israel.
Ilan ShelefDepartment of Diagnostic Imaging, Soroka University Medical Center, Beer Sheva 8410101, Israel.ORCID https://orcid.org/0000-0002-8398-6455
Lyna KamintskyDepartment of Medical Neuroscience and the Brain Repair Center, Dalhousie University, Faculty of Medicine, Halifax, NS B3H 4R2, Canada.
Yonatan SerlinNeurophysiology of Epilepsy Unit, NINDS, National Institutes of Health, Bethesda, MD 20892, USA.
Danielle K SandsmarkDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia 19104, USA.
Alon FriedmanDepartment of Medical Neuroscience and the Brain Repair Center, Dalhousie University, Faculty of Medicine, Halifax, NS B3H 4R2, Canada.ORCID https://orcid.org/0000-0003-4780-8456
Hadar ShalevDepartment of Psychiatry, Soroka University Medical Center, Beer-Sheva 8410101, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Age-related cognitive decline is a common and growing public health challenge, associated with loss of independence, reduced quality of life, increased caregiver burden and substantial healthcare and societal costs. Yet cognitive decline in ageing is heterogeneous, and current clinical constructs do not reliably capture the underlying biological mechanisms or predict progression to dementia. This cross-sectional study examined whether blood-brain barrier dysfunction (BBBD) provides a biologically supported correlate of cognitive performance beyond clinical diagnosis. The study included 46 patients with mild cognitive impairment (MCI), 46 age-matched controls and 43 young controls. BBBD was assessed using dynamic contrast-enhanced MRI in 42 patients with MCI and all controls, alongside volumetric brain analysis. Standardized NeuroTrax cognitive assessment data were analysed for 41 MCI patients and 19 age-matched controls. BBBD was analysed using the BBBdetect software

Indexed as

biomarkersmild cognitive impairmentMRIneuropsychological tests

Identifiers

PMID42909898
PMCPMC13684410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.